Articles

Yes — combining GLP-1 receptor agonist therapy with structured resistance training produces superior fat mass reduction and insulin sensitivity improvement versus GLP-1 monotherapy. A 2026 network meta-analysis across nine RCTs ranked the combination first on weight (SMD −1.04), fat mass, and HOMA-IR, with the exercise arm adding a statistically significant HOMA-IR benefit (SMD −0.28) that pharmacotherapy alone did not achieve.

Current evidence sets the functional floor at 1·2 g per kilogram of total body weight per day during active GLP-1 cut phases. The 2025 AJCN joint advisory refines this to 1·5 g/kg of fat-free mass per day. Observed intake in GLP-1 users averages just 0·6 g/kg/day, directly explaining the 25–39% lean-mass fraction of total weight lost on semaglutide and tirzepatide.

The 2025 Józwiak et al. literature and patent review (Pharmaceuticals 2025, 18, 185; PMC11859134) — now carrying 44 citations — establishes that BPC-157's pleiotropic activity spans at least six organ systems, operates through four distinct receptor-level pathways, and generates metabolites with independent biological activity. For performance practitioners, the mechanistic breadth documented here exceeds what any single-tissue review captures.

Precision nutrition — the systematic calibration of protein quality, micronutrient density, meal timing, and dietary pattern to an individual's metabolic phenotype — measurably shifts lean mass outcomes during GLP-1 receptor agonist therapy. Structured nutritional intervention can reduce the lean-mass fraction of total weight lost from roughly 25–40% to below 15%, according to a 2025 review.

Yes — specific fermentable fibers, particularly resistant dextrins, inulin-type fructans, and mixed-linkage beta-glucans, reliably elevate postprandial GLP-1 by 20–40% above baseline in controlled trials, co-secreting PYY and reducing ad libitum energy intake by 5–10%. The effect is fiber-type dependent, dose-dependent, and mechanistically rooted in colonic SCFA production rather than direct mucosal contact.

Yes — current comparative data show tirzepatide produces larger absolute and proportional fat-mass reductions than semaglutide. DXA sub-studies indicate approximately 83 percent of weight lost as fat versus 60 to 70 percent for semaglutide. Tirzepatide also generates greater suppression of uncontrolled eating and high-fat food cravings, attributable to GIP receptor co-agonism acting on hypothalamic reward circuitry.

Current evidence suggests retatrutide preserves a greater proportion of lean mass than semaglutide during rapid weight loss. Phase 2 DXA data show approximately 17 percent of total weight lost as lean tissue versus semaglutide's 30 to 39 percent in STEP trials. The mechanistic basis involves GIP receptor co-agonism attenuating glucagon-driven protein catabolism. No direct head-to-head lean-mass trial exists in 2026.

Orforglipron, an oral non-peptide GLP-1 receptor agonist approved in 2025, produces appetite suppression and gastric-emptying delay mechanistically identical to injectable GLP-1 agonists — but its daily oral dosing, absence of a food-effect restriction, and flatter pharmacokinetic profile create meaningfully different practical conditions for fasting windows, meal timing, and protein intake management than weekly subcutaneous semaglutide or tirzepatide.

GLP-1/GIP agonists do not directly blunt resistance-training hypertrophy signalling at the receptor level, but systemic AMPK activation creates a catabolic-anabolic conflict that attenuates mTORC1 output by an estimated 15–25%. Post-exercise appetite suppression is additive with the drug's baseline anorexigenic effect, deepening the caloric deficit by 200–400 kcal/day — accelerating fat loss but amplifying lean-mass attrition when protein intake is undefended.

Retatrutide is a triple incretin agonist that produced 24.2 percent mean body-weight loss at 48 weeks in Phase 2, numerically exceeding both semaglutide and tirzepatide. No controlled trial has matched calorie intake and exercise exposure across all three agents. The fat-mass-specific advantage therefore remains mechanistically inferred rather than directly demonstrated in a head-to-head design.

A 2026 Phase 4 trial actively recruiting virally suppressed adults with HIV tests whether tirzepatide's dual GIP/GLP-1 co-agonism can simultaneously reduce epigenetic aging pace and restore metabolic markers — and whether those changes correlate with visceral fat and lean mass shifts. HIV-associated visceral adiposity and chronic immune activation are independent epigenetic clock accelerants; tirzepatide targets both axes simultaneously.

Yes — resistance training fundamentally alters lean-mass outcomes during GLP-1 therapy. Without it, semaglutide users lose 25–40% of total weight as lean tissue. Controlled exercise interventions reduce that fraction to roughly 10–15% by activating a RAGULATOR-independent mTORC1 pathway that operates even under deep caloric deficits, while protein intake above 1.6 g/kg/day adds a mechanistically distinct, additive protective signal.